Capricor Therapeutics Inc CAPR:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/03/24 EDT
5.47quote price arrow up+0.23 (+4.39%)
Volume
259,324
52 week range
2.68 - 8.22
Loading...
  • Open5.28
  • Day High5.78
  • Day Low5.28
  • Prev Close5.24
  • 52 Week High8.22
  • 52 Week High Date08/28/23
  • 52 Week Low2.68
  • 52 Week Low Date11/10/23

Key Stats

  • Market Cap172.321M
  • Shares Out31.50M
  • 10 Day Average Volume0.42M
  • Dividend-
  • Dividend Yield-
  • Beta4.01
  • YTD % Change11.86

KEY STATS

  • Open5.28
  • Day High5.78
  • Day Low5.28
  • Prev Close5.24
  • 52 Week High8.22
  • 52 Week High Date08/28/23
  • 52 Week Low2.68
  • 52 Week Low Date11/10/23
  • Market Cap172.321M
  • Shares Out31.50M
  • 10 Day Average Volume0.42M
  • Dividend-
  • Dividend Yield-
  • Beta4.01
  • YTD % Change11.86

RATIOS/PROFITABILITY

  • EPS (TTM)-0.87
  • P/E (TTM)-6.28
  • Fwd P/E (NTM)-6.59
  • EBITDA (TTM)-23.009M
  • ROE (TTM)-129.63%
  • Revenue (TTM)25.178M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-88.52%
  • Debt To Equity (MRQ)14.94%

EVENTS

  • Earnings Date05/09/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Capricor Therapeutics Inc

 

Profile

MORE
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing...
Frank Litvack M.D.
Executive Chairman of the Board
Linda Marban Ph.D.
President, Chief Executive Officer, Director
Anthony Bergmann
Chief Financial Officer
Karen Krasney J.D.
Executive Vice President, General Counsel
Address
8840 Wilshire Blvd, 2nd Floor
Beverly Hills, CA
90211
United States

Top Peers

SYMBOLLASTCHG%CHG
BLUE
bluebird bio Inc
0.8998-0.0035-0.3875%
ZVRA
Zevra Therapeutics Inc
4.81+0.06+1.26%
HOWL
Werewolf Therapeutics Inc
6.07-0.01-0.16%
PRQR
ProQR Therapeutics NV
2.01+0.02+1.01%
CLLS
Cellectis SA
2.99UNCHUNCH